--- title: "BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target" type: "News" locale: "en" url: "https://longbridge.com/en/news/285424618.md" description: "TD Cowen analyst Stacy Ku has reiterated a Buy rating on BioCryst (BCRX) stock, citing the strength of the Orladeyo franchise and the company's attractive valuation. Orladeyo shows strong demand with double-digit growth and stable prescriber additions, with a 2026 revenue guidance of $625–645 million. BioCryst trades at a discount, with potential for significant sales growth. Ku maintains a $30 price target, supported by positive physician feedback and long-term growth prospects. Needham also maintains a Buy rating with a $16 price target." datetime: "2026-05-06T19:17:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285424618.md) - [en](https://longbridge.com/en/news/285424618.md) - [zh-HK](https://longbridge.com/zh-HK/news/285424618.md) --- # BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target TD Cowen analyst Stacy Ku has maintained their bullish stance on BCRX stock, giving a Buy rating today. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Stacy Ku has given his Buy rating due to a combination of factors tied mainly to the durable Orladeyo franchise and the company’s attractive valuation. Orladeyo continues to show strong underlying demand with double‑digit year‑over‑year growth, stable prescriber additions, and management reaffirming 2026 revenue guidance of $625–645 million, supported by anticipated pediatric use once a manageable manufacturing issue is resolved. Ku further highlights that BioCryst trades at a notable discount at roughly 2x projected 2027 revenue despite intellectual property protection into 2039 and the potential for both Orladeyo and navenibart to each reach roughly $1 billion in peak HAE sales. Physician feedback indicates Orladeyo should remain the leading oral prophylactic option with strong five‑year patient retention, while navenibart is poised to become a preferred injectable, supporting a long runway of growth and justifying the reiterated $30 price target. Ku covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Aurinia Pharmaceuticals, and Protara Therapeutics. According to TipRanks, Ku has an average return of 13.8% and a 56.12% success rate on recommended stocks. In another report released today, Needham also maintained a Buy rating on the stock with a $16.00 price target. ### Related Stocks - [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [TD.US](https://longbridge.com/en/quote/TD.US.md) - [SUPN.US](https://longbridge.com/en/quote/SUPN.US.md) - [AUPH.US](https://longbridge.com/en/quote/AUPH.US.md) - [TARA.US](https://longbridge.com/en/quote/TARA.US.md) ## Related News & Research - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md) - [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)